In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to ...

At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

A third dose of the Pfizer/BioNTech COVID-19 vaccine can "strongly" boost protection against the delta variant -- beyond the protection afforded by the standard two doses, suggests new data released ...

ABRYSVO, a bivalent vaccine, maintained consistently high protective efficacy for both RSV A and RSV B disease through two seasons after a single dose. ABRYSVO efficacy was 77.8% against RSV lower ...

At Pfizer, the certification recognises the company’s Analytics Gateway and broader data science ecosystem, where teams work ...

US pharma giant Pfizer on Saturday announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...

Add Yahoo as a preferred source to see more of our stories on Google. A vial of the Pfizer/BioNTech Comirnaty vaccine against Covid-19 at a mass vaccination center on July 1, 2021 in Leipzig, Germany.